> > >

MixPro® Reconstitution Video

A patient-friendly video you can share to provide patients an overview on how to correctly prepare Esperoct® for infusion with MixPro®.

Please see full Prescribing Information and Important Safety Information.

Play
Pause
Skip
Volume
Chapters
Transcript
References
video_su
Fullscreen

MixPro® Reconstitution Video

Chapters
Transcript
References

A patient-friendly video you can share to provide patients an overview on how to correctly prepare Esperoct® for infusion with MixPro®.

Please see full Prescribing Information and Important Safety Information.

Return to overview

Chapters

Return to overview

Transcripts

Return to overview

References


Additional Information

We’ve created additional resources to address your questions.

Choose from these materials:

Esperoct® Brochure for HCPs

Esperoct® MOA Video

Selected Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications
  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
Adverse Reactions
  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Prescribing Information